China's BeiGene Starts Combination Trial for Two Novel Cancer Drugs

BeiGene, a Beijing novel cancer biopharma, has dosed the first patient in a Phase I trial that combines a targeted BTK inhibitor with a PD-1 immuno-oncology antibody. BeiGene developed both molecules in-house. The trial, which will enroll 25 patients with B-cell lymphoid malignancies, will be conducted in Australia. BeiGene has another combination trial already underway. The earlier trial pairs the PD-1 immuno-oncology drug with a PARP inhibitor. More details.... Stock Symbol: (NSDQ: BGNE) Share this with colleagues: // //